Suchergebnisse - "Schott, Anne F"

PubPharm (102)

1

Investigating potential disparities in clinical trial eligibility and enrollment at an NCI-designated comprehensive cancer center

enthalten in: Cancer medicine | 2023

von Patel, M. | Shah, J. | Brinley, F. | +3

2

Investigating potential disparities in clinical trial eligibility and enrollment at an NCI‐designated comprehensive cancer center

enthalten in: Cancer Medicine | 2023

von Patel, M. | Shah, J. | Brinley, F. | +3

3

Envisioning clinical trials as complex interventions

enthalten in: Cancer | 2022

von Stensland, K. | Damschroder, L. | Sales, A. | +2

4

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Moore, H. | Barlow, W. | Somlo, G. | +14

5

Envisioning clinical trials as complex interventions

enthalten in: Cancer | 2022

von Stensland, K. | Damschroder, L. | Sales, A. | +2

6

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

enthalten in: The New England journal of medicine | 2021

von Kalinsky, K. | Barlow, W. | Gralow, J. | +31

CommentIn: Nat Rev Clin Oncol. 2022 Feb;19(2):72. - PMID 34912052

7

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

enthalten in: Breast cancer research and treatment | 2021

von Goldstein, L. | Mansutti, M. | Levy, C. | +52

8

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

enthalten in: Breast cancer research and treatment | 2021

von Goldstein, L. | Mansutti, M. | Levy, C. | +11

9

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

enthalten in: Breast cancer research and treatment | 2021

von Goldstein, L. | Mansutti, M. | Levy, C. | +11

10

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

enthalten in: Breast cancer research and treatment | 2021

von Goldstein, L. | Mansutti, M. | Levy, C. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]